Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource Medicine Commercial Holdings Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co. Ltd. The partnership aims to expand and unite efforts to carry out in-depth cooperation in traditional medicine, innovative projects, patient management, internet healthcare, and other fields. This alliance is designed to enhance the service value of the three parties within the pharmaceutical industry.
Eisai’s Stronger Neo-Minophagen C (SNMC, compound glycyrrhizin), developed by Japan-based Minophagen, received marketing approval in China in 2000. SNMC is an injectable preparation of Glycyrrhizin, extracted from the saponin component found in the roots of the licorice plant, used to improve abnormal hepatic function in patients with chronic hepatic diseases.
In July 2007, Eisai secured a licensing deal with Minophagen, gaining exclusive development and marketing rights to the drug in Japan and Eurasian countries and regions where the drug was not yet commercially available. For countries and regions in Eurasia where the drug was already on the market, Eisai obtained exclusive priority negotiation rights. On April 1, 2009, Eisai took over marketing activities for the drug in the Chinese market.
This strategic partnership with China Resource Medicine and China Resources Sanjiu is expected to leverage Eisai’s pharmaceutical expertise and the resources of its Chinese partners to broaden the reach and impact of their pharmaceutical offerings, particularly in the areas of traditional medicine and digital healthcare.- Flcube.com
